fenofibrate has been researched along with simvastatin in 173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.16) | 18.7374 |
| 1990's | 32 (18.50) | 18.2507 |
| 2000's | 62 (35.84) | 29.6817 |
| 2010's | 71 (41.04) | 24.3611 |
| 2020's | 6 (3.47) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, A; Alvaro, R; Berger, JP; Cai, TQ; Dropinski, JF; Heck, JV; Hernandez, M; Macnaul, KL; Meinke, PT; Moller, DE; Sahoo, SP; Santini, C; Shi, GQ; Wright, SD; Zhang, Y; Zhou, G | 1 |
| Agrawal, A; Berger, JP; Cai, TQ; Desai, RC; Heck, JV; MacNaul, KL; Meinke, PT; Metzger, E; Moller, DE; Sahoo, SP; Santini, C; Wright, SD | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O | 2 |
| Schlienger, JL | 1 |
| Agheli, N; Jacotot, B | 1 |
| Drouin, P; Ziegler, O | 1 |
| Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fricker, J; Keller, U | 1 |
| Keller, U; Riesen, WF; Stohler, R | 1 |
| Brown, WV | 1 |
| Duncan, A; Murphy, MJ; O'Reilly, DS; Packard, CJ; Vallance, BD | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Hockwin, O; Paulus, U; Schmidt, J; Schmitt, C; von Bergmann, K | 1 |
| Ben Khalifa, F; Ftouhi, B; Kaabachi, A; Mebazaa, R; Mekaouer, A; Turki, S | 1 |
| Amouyel, P; Brousseau, T; Devulder, B; Fruchart, JC; Lecerf, JM; Luc, G | 1 |
| Shepherd, J | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 1 |
| Bonnefous, F; Debbas, N; Farnier, M; Irvine, A | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Hehnke, U; Kaffarnik, H; Schwartz, T; Steinmetz, A | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Durrington, P | 1 |
| Adkins, JC; Faulds, D | 1 |
| Cheung, J; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Ellen, RL; McPherson, R | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Sinzinger, H | 1 |
| Hall, RR | 1 |
| de Lorgeril, M; Lacan, P; Paillard, F; Richard, G; Salen, P | 1 |
| Belichard, P; Bontemps, L; de Lorgeril, M; Geyssant, A; Itti, R; Salen, P | 1 |
| Kirchgässler, KU; Schiffner-Rohe, J; Stahlheber, U | 1 |
| Kayikçioğlu, M; Ozerkan, F; Soydan, I | 1 |
| Bartek, J; Růzicka, V; Stejskal, D | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Caroli-Bosc, C; Caroli-Bosc, FX; Delabre, B; Delmont, JP; Demarquay, JF; Le Gall, P; Montet, JC; Pugliese, P; Rampal, P | 1 |
| Chang, J; Cheng, JS; Pasceri, V; Willerson, JT; Yeh, ET | 1 |
| Galli, C; Pazzucconi, F; Risé, P; Sirtori, CR | 1 |
| Akhmedzhanov, NM; Oganov, RG; Olfer'ev, AM; Ozerova, IN; Paramonova, IV; Pavlova, LI; Perova, NV | 1 |
| Garber, BG; McDonald, KB; Perreault, MM | 1 |
| Waterman, IJ; Zammit, VA | 1 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Császár, A; Márk, L | 1 |
| Barouki, R; Gouédard, C; Koum-Besson, N; Morel, Y | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M | 2 |
| Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Chen, MF; Chen, WJ; Cheng, CC; Lee, YT; Lin, JW; Wang, TD | 1 |
| Romaniv, S; Vecka, M; Zák, A; Zeman, M | 1 |
| Burhenne, J; Ehrhardt, M; Haefeli, WE; Lindenmaier, H; Weiss, J | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H | 1 |
| Bergman, AJ; Burke, J; Hartford, A; He, W; Lasseter, KC; Liu, L; Murphy, G; Paolini, JF; Prueksaritanont, T; Qiu, Y; Valesky, R; Vega, JM; Zhao, JJ | 1 |
| Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Kłosiewicz-Latoszek, L; Stolarska, I; Szostak, WB; Wiśniewska, B | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jeong, EM; Jin, DK; Kim, HS; Koh, KK; Shin, EK | 1 |
| Battisti, WP; Brady, WE; Grundy, SM; Palmisano, J; Vega, GL; Yuan, Z | 1 |
| Deeg, MA; Jacob, S; Jacob, SS; Williams, C | 1 |
| Boucher, F; de Leiris, J; de Lorgeril, M; Guiraud, A; Salen, P; Zeghichi, S | 1 |
| Chen, H; Luo, Y; Ren, JY | 1 |
| Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Celinska-Lowenhoff, M; Potaczek, DP; Szczeklik, A; Undas, A | 2 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Celińska-Lowenhoff, M; Nizankowski, R; Stepień, E; Szczeklik, A; Tracz, W; Undas, A | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD | 1 |
| Bernini, F; Calabresi, L; Colombo, C; Favari, E; Franceschini, G; Sirtori, CR | 1 |
| Game, BA; He, L; Huang, Y; London, SD; Lopes-Virella, MF; Maldonado, A; Nareika, A; Sanders, JJ; Slate, EH | 1 |
| Davies, MJ; Farnier, M; Gil-Extremera, B; Hamlin, C; Kush, D; Macdonell, G; Mendez, GF; Mitchel, YB; Perevozskaya, I; Roth, E | 1 |
| Brundel, BJ; Burstein, B; Leung, TK; Mitamura, H; Nattel, S; Ogawa, S; Shiroshita-Takeshita, A | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Cai, G; Du, L; Su, H; Wang, W; Xie, W; Xing, D | 1 |
| Bal, BS; Kant, R; Mahajan, M; Sharma, R; Singh, B | 1 |
| Celińska-Löwenhoff, M; Gluszko, P; Löwenhoff, T; Undas, A | 1 |
| Carissimi, R; Galli, C; Ghezzi, S; Mastromauro, F; Petroni, A; Risé, P | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koragiannis, A; Mikhailidis, DP; Mikhalidis, DP | 1 |
| Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M | 1 |
| Besson, VC; Beziaud, T; Chen, XR; Marchand-Leroux, C; Plotkine, M | 1 |
| Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Abe, Y; Hata, K; Hiwatashi, K; Itoh, M; Iwama, Y; Kimura, F; Sasaki, H; Satoh, M; Shoji, M; Takahashi, J; Toshima, G | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Grundy, SM; Tershakovec, AM; Tomassini, JE; Vega, GL | 2 |
| Visseren, FL; Westerink, J | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Bigger, JT; Buse, JB; Byington, RP; Crouse, JR; Cushman, WC; Elam, MB; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Ismail-Beigi, F; Leiter, LA; Linz, P; Lovato, LC; Probstfield, J; Simons-Morton, DG | 1 |
| Nilsson, PM | 1 |
| Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM | 1 |
| Klein, BE | 1 |
| Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U | 1 |
| Pérez, A | 1 |
| Drexel, H; Rein, P; Saely, CH | 1 |
| Chen, L; Tonkin, AM | 1 |
| Perkins, WJ | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopien, B | 2 |
| Atkinson, BJ; Pagliaro, LC; Watkins, JL | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Dodson, PM; Wright, AD | 1 |
| Ginsberg, HN | 1 |
| Cho, DH; Joe, DH; Kang, HC; Park, HY; Yun, SJ | 1 |
| Elisaf, MS; Filippatos, TD | 2 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A | 1 |
| Prasad, V; Vandross, A | 1 |
| Filippatos, TD | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Chang, CN; How, CH; Tavintharan, S | 1 |
| Ginsberg, HN; Holleran, S; Karmally, W; Lovato, L; Ngai, CI; Ramakrishnan, R; Reyes-Soffer, G | 1 |
| Ceska, R; Marinov, I; Skrha, J; Stulc, T | 1 |
| Al-Dughaishi, T; Al-Hashmi, K; Al-Hinai, AT; Al-Rasadi, K; Al-Sabti, H; Al-Waili, K; Al-Zakwani, I; Baneerje, Y; Farhan, H; Habsi, KA | 1 |
| Bastiaansen-Jenniskens, YM; Bierma-Zeinstra, SM; Botter, SM; Clockaerts, S; Gierman, LM; Kloppenburg, M; van Osch, GJ; Verhaar, JA; Wei, W; Weinans, H; Zuurmond, AM | 1 |
| Byington, RP; Crouse, JR; Elam, MB; Force, RW; Ginsberg, HN; Ismail-Beigi, F; Leiter, LA; Linz, PE; Lovato, LC; O'Connor, PJ; Papademetriou, V; Simmons, DL; Weiss, D | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Ansquer, JC; Aubonnet, P; Beckmann, K; Driessen, S; Lehnick, D; Mihara, K; Olbrich, M; Piskol, G; van Amsterdam, P; van Assche, H; Winsemius, A | 1 |
| Ashok, P; Poulose, DN; Singh, D; Suresh, B | 1 |
| Cui, GB; Liu, L; Liu, YH; Ma, B; Sun, JJ; Wu, ZM; Xu, QY; Yang, ZD; Yao, D; Zhang, Q | 1 |
| Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M | 1 |
| Gdula-Dymek, A; Krysiak, R; Marek, B; Okopień, B | 2 |
| Aubonnet, P; Belenky, D; Berli, M; Calvo Vargas, CG; Foucher, C; Koch, HF; Lochocka, A; Reichert, P; Schaeffer, A | 1 |
| Chelcea, RI; Demco, DE; Fechete, R; Moldovan, D; Pap, Z; Pávai, Z; Şipoş, RS | 1 |
| Amigó, N; Blanco Vaca, F; Correig, X; Escolà-Gil, JC; Heras, M; Mallol, R; Martínez-Hervás, S; Masana, L; Plana, N; Yanes, Ó | 1 |
| Amr, G; Azzaoui, R; Bordet, R; Delassus, L; Fossaert, E; Modine, T; Ouk, T; Tailleux, A | 1 |
| Baulard, A; Daffé, M; Denis, O; Fontaine, V; Frita, R; Laval, F; Lefèvre, P; Rens, C; Wattiez, R | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Gaglione, A; Guastafierro, F; Santoro, F; Tarantino, N | 1 |
| Abbassi, MM; Abdel Magid, AM; Farid, SF; Iskander, EEM; Mohamady, O | 1 |
| Buranasupkajorn, P; Buse, JB; Doria, A; Gao, H; Gerstein, HC; Hastings, T; Kraft, P; Marcovina, SM; Mendonca, C; Morieri, ML; Motsinger-Reif, AA; Mychaleckyj, JC; Parè, G; Pigeyre, M; Rotroff, DM; Shah, HS; Sigal, RJ; Sjaarda, J; Wagner, MJ | 1 |
| Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL | 1 |
| Ambrosius, WT; Beddhu, S; Boucher, R; Bress, AP; Chertow, GM; Cheung, AK; Cushman, WC; Cutler, J; Fine, L; Greene, T; Kimmel, PL; Kramer, H; Lewis, CE; Oparil, S; Rahman, M; Wei, G; Whelton, PK; Zhang, C | 1 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Li, G; Qiu, F; Sun, Y; Zhao, L; Zhao, M | 1 |
| Bilušić, M; Blažević, N; Bradamante, V; Konjevoda, P; Lovrić, J; Vukšić, A | 1 |
| Bell, KJL; Hayen, A; Zhu, L | 1 |
| Abbouda, A; Cunha, DL; Horneffer-van der Sluis, V; Mitsios, A; Moosajee, M; Owen, N; Richardson, R; Skinner, J; Takis, P; Tracey-White, D; Welch, AA | 1 |
| Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M | 1 |
| Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F | 1 |
| Fechete, R; Micu, AM; Orban, E; Pap, Z; Sipos, RS | 1 |
| Bilušić, M; Božina, T; Bradamante, V; Konjevoda, P; Lovrić, J; Rašić, D; Vukšić, A; Žunec, S | 1 |
19 review(s) available for fenofibrate and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin | 1997 |
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin | 2004 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Practice Guidelines as Topic; Simvastatin | 2009 |
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Lipids; Middle Aged; Simvastatin | 2011 |
A case of xanthoma disseminatum with spontaneous resolution over 10 years: review of the literature on long-term follow-up.
Topics: Adolescent; Amenorrhea; Anetoderma; Antidiuretic Agents; Biopsy; Cicatrix; Deamino Arginine Vasopressin; Dermatologic Agents; Diabetes Insipidus; Female; Fenofibrate; Gadolinium DTPA; Histiocytosis, Non-Langerhans-Cell; Hormone Replacement Therapy; Humans; Radionuclide Imaging; Remission, Spontaneous; Simvastatin | 2011 |
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Drug Combinations; Drug Monitoring; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Risk Factors; Simvastatin | 2011 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
Safety considerations with fenofibrate/simvastatin combination.
Topics: Drug Combinations; Drug Interactions; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.
Topics: Animals; Biomarkers; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Simvastatin; Treatment Outcome; Triglycerides | 2017 |
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
76 trial(s) available for fenofibrate and simvastatin
| Article | Year |
|---|---|
A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Female; Fenofibrate; Humans; Hypercholesterolemia; In Vitro Techniques; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Lipoprotein particle analysis comparing simvastatin and fenofibrate.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Middle Aged; Simvastatin | 1991 |
Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol Esters; Double-Blind Method; Fatty Acids; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Phospholipids; Simvastatin; Triglycerides | 1991 |
Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
[The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Simvastatin | 1990 |
Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Propionates; Simvastatin; Triglycerides | 1989 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
[Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Prognosis; Simvastatin; Triglycerides | 1994 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Simvastatin; Triglycerides | 1997 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Lipid-lowering drugs and homocysteine.
Topics: Amino Acids; Coronary Disease; Double-Blind Method; Fenofibrate; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Simvastatin | 1999 |
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; Female; Fenofibrate; Fibrinogen; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Patient Dropouts; Physical Endurance; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1999 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1997 |
Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Simvastatin | 1999 |
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)].
Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Pravastatin; Proteins; Simvastatin | 1998 |
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Simvastatin | 2003 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
Topics: C-Reactive Protein; CD40 Antigens; CD40 Ligand; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Inflammation Mediators; Interleukin-1; Lipids; Male; Middle Aged; Simvastatin; Vasodilation | 2003 |
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2003 |
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Topics: Acetylglucosaminidase; Adult; Aged; alpha-Tocopherol; Ascorbic Acid; Cholesterol; Czech Republic; Diabetes Mellitus, Type 2; Drug Administration Schedule; E-Selectin; Endothelium; Female; Fenofibrate; Fibrinolysis; Glutathione; Humans; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Plasminogen Activator Inhibitor 1; Simvastatin; Superoxide Dismutase; Time Factors; Triglycerides; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2004 |
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Topics: Adolescent; Adult; Area Under Curve; Biotransformation; Blood Cell Count; Cross-Over Studies; Drug Interactions; Electrocardiography; Female; Fenofibrate; Half-Life; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Male; Microsomes, Liver; Middle Aged; Simvastatin | 2004 |
Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.
Topics: Brachial Artery; Coronary Artery Disease; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Matrix Metalloproteinases; Middle Aged; Nitrates; Nitric Oxide; Simvastatin; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha; Vasodilation | 2004 |
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Topics: Adult; Aged; Alanine Transaminase; Apolipoproteins; Aspartate Aminotransferases; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Muscular Diseases; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
Topics: Analysis of Variance; Coronary Disease; Diet, Mediterranean; Double-Blind Method; Drug Synergism; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2005 |
[Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
Topics: Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2005 |
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antithrombins; beta-Thromboglobulin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Fibrinolytic Agents; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Microscopy, Electron, Scanning; Platelet Activation; Simvastatin; Thrombin; Time Factors; Triglycerides | 2005 |
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients.
Topics: Biomarkers; C-Reactive Protein; CD40 Ligand; Female; Fenofibrate; Genetic Predisposition to Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Interleukin-6; Male; Middle Aged; P-Selectin; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Prospective Studies; Simvastatin; Statistics, Nonparametric | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury.
Topics: Adult; Aged; Angiogenic Proteins; Anticholesteremic Agents; Becaplermin; Bleeding Time; CD40 Ligand; Female; Fenofibrate; Hemostatic Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Simvastatin; Vascular Endothelial Growth Factor A | 2006 |
The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects.
Topics: Alleles; Female; Fenofibrate; Genotype; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Simvastatin | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Phospholipases A; Phospholipases A2; Simvastatin | 2006 |
Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients.
Topics: Aged; Apolipoproteins; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Scavenger Receptors, Class B; Simvastatin | 2007 |
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Topics: Azetidines; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Simvastatin; Treatment Outcome | 2006 |
Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.
Topics: Bone Density; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Osteoprotegerin; RANK Ligand; Simvastatin; Solubility | 2007 |
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Triglycerides | 2008 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides; Young Adult | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Sex Factors; Simvastatin; Stroke; Treatment Failure; Triglycerides | 2010 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2010 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome | 2011 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Male; Placebo Effect; Simvastatin | 2011 |
Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
Topics: Apolipoproteins B; Cholesterol, LDL; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Immunoassay; Magnetic Resonance Spectroscopy; Prognosis; Reproducibility of Results; Simvastatin; Triglycerides | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
Topics: Adult; Aged; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Lipids; Lymphocytes; Male; Middle Aged; Simvastatin; Treatment Outcome | 2013 |
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.
Topics: Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period; Simvastatin | 2013 |
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Topics: Adult; CD11a Antigen; CD18 Antigens; Cross-Over Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Integrin alpha4; Leukocytes; Lipids; Lipopolysaccharide Receptors; Male; Middle Aged; Simvastatin | 2012 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome | 2014 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Factors; Risk Reduction Behavior; Simvastatin; Stroke | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?
Topics: Cholesterol; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Triglycerides | 2014 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cystatin C; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2015 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Simvastatin | 2016 |
Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis.
Topics: Anticholesteremic Agents; Blood Pressure; Drug Administration Schedule; Female; Fenofibrate; Glutathione Peroxidase; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Renal Dialysis; Simvastatin; Treatment Outcome; Triglycerides | 2017 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fenofibrate; Genetic Association Studies; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Simvastatin | 2018 |
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Simvastatin; Time Factors | 2018 |
Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Male; Middle Aged; Prognosis; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome; United States | 2018 |
Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects.
Topics: Adult; Berberine; China; Chromatography, Liquid; Drug Administration Schedule; Drug Interactions; Female; Fenofibrate; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2019 |
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2020 |
79 other study(ies) available for fenofibrate and simvastatin
| Article | Year |
|---|---|
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
Topics: Animals; Benzofurans; Carboxylic Acids; Cholesterol; Cricetinae; Dogs; Humans; Hyperlipidemias; Hypolipidemic Agents; In Vitro Techniques; Male; Mesocricetus; Molecular Conformation; PPAR alpha; Radioligand Assay; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triglycerides | 2005 |
Design and synthesis of potent and subtype-selective PPARalpha agonists.
Topics: Animals; Cricetinae; Dogs; Drug Design; Dyslipidemias; Haplorhini; Hypolipidemic Agents; Molecular Structure; PPAR alpha; Rats; Structure-Activity Relationship; Transcriptional Activation | 2006 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Drug Interactions; Female; Fenofibrate; Humans; Hypolipoproteinemias; Lovastatin; Male; Middle Aged; Probucol; Simvastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Ocular drug safety and HMG-CoA-reductase inhibitors.
Topics: Color Perception; Contrast Sensitivity; Eye; Female; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intraocular Pressure; Lens, Crystalline; Lovastatin; Male; Middle Aged; Photography; Refraction, Ocular; Safety; Simvastatin; Visual Acuity | 1994 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Polymerase Chain Reaction; Simvastatin | 1995 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
Detecting and correcting hyperlipidemia.
Topics: Algorithms; Decision Trees; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postmenopause; Simvastatin | 1998 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Topics: Anticholesteremic Agents; Cholelithiasis; Double-Blind Method; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pregnancy; Risk Factors; Simvastatin | 2001 |
Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.
Topics: C-Reactive Protein; Cells, Cultured; Chemokine CCL2; Chemokine CCL5; Dose-Response Relationship, Drug; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Simvastatin; Time Factors; Transcription Factors | 2001 |
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Arachidonic Acid; Cholesterol; Cholesterol, LDL; Diet, Reducing; Fatty Acids; Female; Fenofibrate; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 2001 |
Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Cardiolipins; Cholesterol; Cholesterol, HDL; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Lysophosphatidylcholines; Male; Middle Aged; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Simvastatin; Sphingomyelins; Triglycerides | 2001 |
Pancreatitis associated with simvastatin plus fenofibrate.
Topics: Aged; Drug Therapy, Combination; Fatal Outcome; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pancreatitis, Acute Necrotizing; Simvastatin | 2002 |
Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities.
Topics: Acyltransferases; Animals; Diacylglycerol O-Acyltransferase; Diet; Fatty Acids, Omega-3; Female; Fenofibrate; Hypolipidemic Agents; Liver; Microsomes, Liver; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2002 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins.
Topics: Aryldialkylphosphatase; Carboxylic Ester Hydrolases; DNA; Esterases; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Gene Expression Regulation, Enzymologic; Humans; Hypolipidemic Agents; Indoles; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Tumor Cells, Cultured | 2003 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.
Topics: Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Simvastatin | 2003 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Dihydroergocryptine; Fenofibrate; Humans; Hypolipidemic Agents; Simvastatin; Swine; Transfection | 2004 |
Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2004 |
Simvastatin, fenofibrate, and rhabdomyolysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Rhabdomyolysis; Simvastatin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin.
Topics: Chemokines; Cytokines; Fenofibrate; Glucose; Histiocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipopolysaccharides; Nitric Oxide; Nitric Oxide Synthase Type II; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Simvastatin; Thiazolidinediones; Time Factors; U937 Cells | 2007 |
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
Topics: Actins; Animals; Anti-Inflammatory Agents; Atrial Fibrillation; Biomarkers; Cardiac Pacing, Artificial; Cell Proliferation; Cells, Cultured; Dogs; Fenofibrate; Fibroblasts; Heart Atria; Heart Failure; Heart Ventricles; Hypolipidemic Agents; Models, Animal; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; PPAR alpha; Refractory Period, Electrophysiological; Simvastatin; Tyrosine; Ventricular Remodeling | 2007 |
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Topics: Ananas; Animals; Blood Glucose; Cholesterol; Dietary Fats; Dose-Response Relationship, Drug; Enzyme Activation; Ethanol; Fenofibrate; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Mice; Mice, Inbred ICR; Plant Extracts; Plant Leaves; Simvastatin; Triglycerides | 2007 |
Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.
Topics: Anticholesteremic Agents; Arachidonic Acid; Cell Line; Cholesterol; Delta-5 Fatty Acid Desaturase; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Induction; Fatty Acid Desaturases; Fenofibrate; Humans; Linoleic Acid; Lipid Metabolism; Monocytes; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Pyrimidines; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Time Factors; Transcription, Genetic | 2007 |
Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Simvastatin; Treatment Outcome | 2008 |
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Topics: Animals; Brain Injuries; Disease Models, Animal; Drug Therapy, Combination; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PPAR alpha; Rats; Rats, Sprague-Dawley; Simvastatin | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
HPLC analysis of lipoproteins in culture medium of hepatoma cells: an in vitro system for screening antihyperlipidemic drugs.
Topics: Apolipoprotein A-I; Apolipoprotein B-100; Cell Line, Tumor; Chromatography, High Pressure Liquid; Culture Media; Fenofibrate; Gene Expression Profiling; Hepatocytes; Humans; Hypolipidemic Agents; Lipoproteins; Simvastatin; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2 | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
ACCORD and Risk-Factor Control in Type 2 Diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hypertension; Hypolipidemic Agents; Risk Factors; Simvastatin | 2010 |
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Simvastatin | 2010 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Proportional Hazards Models; Risk; Simvastatin; Triglycerides | 2010 |
Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Lipids; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Simvastatin; Triglycerides | 2010 |
Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Prostatic Neoplasms; Renal Dialysis; Rhabdomyolysis; Simvastatin | 2011 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
Beyond low-density lipoprotein cholesterol: why, who and when.
Topics: Coronary Disease; Drug Therapy, Combination; Exercise; Fenofibrate; Humans; Hypertriglyceridemia; Hypoalphalipoproteinemias; Hypolipidemic Agents; Life Style; Male; Middle Aged; Simvastatin | 2012 |
Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Topics: Aged; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Oman; Practice Guidelines as Topic; Retrospective Studies; Simvastatin; Treatment Outcome | 2014 |
Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice.
Topics: Animals; Arthritis, Experimental; Biomarkers; Body Weight; Cartilage, Articular; Diet; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Mice; Mice, Inbred Strains; Osteoarthritis; Simvastatin; X-Ray Microtomography | 2014 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Feces; Female; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Plant Extracts; Polyethylene Glycols; Rats; Rats, Wistar; Simvastatin | 2014 |
Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.
Topics: 3-Hydroxybutyric Acid; Animals; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Diet, High-Fat; Fenofibrate; Hyperlipidemias; Isoleucine; Linoleic Acid; Male; Metabolome; Metabolomics; Ornithine; Rats; Rats, Sprague-Dawley; Simvastatin; Tyrosine | 2014 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Sex Factors; Simvastatin | 2015 |
Ovariectomized rats' femur treated with fibrates and statins. Assessment of pore-size distribution by ¹H-NMR relaxometry.
Topics: Animals; Female; Femur; Fenofibrate; Fibric Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ovariectomy; Proton Magnetic Resonance Spectroscopy; Rats; Rats, Wistar; Simvastatin | 2015 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Indoles; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Middle Aged; Niacin; Simvastatin; Surface Properties; Triglycerides | 2016 |
Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass.
Topics: Animals; Avoidance Learning; Cardiopulmonary Bypass; Cerebrovascular Disorders; Cognition Disorders; Endothelium, Vascular; Fenofibrate; Hemodynamics; Hypolipidemic Agents; Lipids; Male; Maze Learning; Neurons; Neuroprotective Agents; Rats, Sprague-Dawley; Simvastatin; Tumor Necrosis Factor-alpha; Vasodilation | 2016 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Retrospective Studies; Simvastatin; Treatment Outcome; Young Adult | 2016 |
Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Fenofibrate; Hypolipidemic Agents; Lactones; Membrane Lipids; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium tuberculosis; Orlistat; Simvastatin; Vancomycin | 2016 |
Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Brain; Butyrylcholinesterase; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Liver; Plasma; Rats; Rats, Wistar; Simvastatin | 2019 |
REP1 deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Case-Control Studies; Choroideremia; Fenofibrate; Glycerophospholipids; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipidomics; Male; Metabolomics; Middle Aged; Oxidative Stress; Prenylation; Serotonin; Simvastatin; Sphingolipids; Tryptophan; Young Adult; Zebrafish; Zebrafish Proteins | 2021 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin | 2021 |
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose; Heart Failure; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Simvastatin | 2022 |
Callus formation in albino Wistar rats after femur fracture assessed by visible spectroscopy.
Topics: Animals; Bony Callus; Eosine Yellowish-(YS); Female; Femoral Fractures; Femur; Fenofibrate; Fracture Healing; Hematoxylin; Humans; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Rats, Wistar; Simvastatin; Spectrum Analysis | 2022 |
The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats.
Topics: Animals; Antioxidants; Brain; Fenofibrate; Glutathione; Liver; Male; Malondialdehyde; Rats; Rats, Wistar; Rats, Zucker; Simvastatin | 2023 |